The Safety and Effects of Mesenchymal Stem Cell (MSCs) in the Treatment of Rheumatoid Arthritis

Rheumatoid Arthritis Clinical Trial

Official title:

The Effects and Safety of Mesenchymal Stem Cells in the Treatment of Moderate/Severe Rheumatoid Arthritis， a Multicenter Randomized Controlled Clinical Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03798028
• Other study ID #: 2014ZX09508002
• Status: Recruiting
• Phase: N/A
• Start date: December 26, 2017
• Est. completion date: June 30, 2020

Study information

• Verified date: December 2018
• Source: Xijing Hospital
• Contact: Ping Zhu, Doctor
• Phone: 86-29-84773951
• Email: zhuping[@]fmmu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the safety and therapeutic effects of single-dose human umbilical cord blood mesenchymal stem cells (UC-MSCs) on the adult patients with moderate/severe Rheumatoid Arthritis accompany with anemia or/and Interstitial pulmonary disease. Half of participants will receive UC-MSCs and keep the present medication,while the other half will receive a placebo and keep the present medication.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 250
• Est. completion date: June 30, 2020
• Est. primary completion date: December 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Fulfill 2010 ACR/ the European League Against Rheumatism (EULAR) classification criteria or the 1987 ACR classification criteria.

2. Age limits:18 to 70 years old.

3. Freely given informed consent.

4. Disease Activity Score (DAS) 28=3.2? Simple Disease Activity Index (SDAI)>11.0? Clinical Disease Activity Index (CDAI) >10.0.

5. Hemoglobin < 90 g/L and/or interstitial lung disease shown in high resolution CT.

6. Poor response to current treatment. The current treatment refers to receive the medicines (including Leflunomide, Methotrexate, Sulphasalazine, Hydroxychloroquine, Cyclosporine A,and Tacrolimus, alone or in combination ) for 3 months, and maintain the stable-dose of drugs for at least 1 month.

7. More than 3 months and a stable dose for at least 1 month are required if glucocorticoid is used. The dose of glucocorticoid is less than or equal to10mg/ day of prednisone.

Exclusion Criteria:

1. Participants who received glucocorticoid therapy by intra-articular injection within 1 week.

2. Glucocorticoid that participants received is more than 10 mg/day of prednisone within 1 months.

3. Complication with other connective tissue disease (except for Sjogren syndrome) .

4. Participants with chronic and acute infection (bacteria, virus and parasite,etc.).

5. Participants with acute and chronic tuberculosis infection.

6. Malignant tumors or participants with a family history of malignant tumors.

7. Participants have a family history of allergic conditions.

8. Participants infected by Hepatitis B Virus(HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV).

9. Participants suffer from central nervous system demyelinating disease or multiple sclerosis (MS) currently or in the past.

10. Participants received live vaccines with 3 months.

11. Drug abuse and alcoholism.

12. Participants with severe mental or neurological disorders that affect informed consent and/or the presentation or observer of adverse events.

13. Participants with pregnant or in breast-feeding, and patients who has a pregnancy plan within 1 year.

14. Participants received stem cell therapy in the past.

15. Participants received any biological agents within 3 months.

16. Anemia (such as anemia with dysplasia) and interstitial lung disease for other reasons.

17. Participants with cardiovascular and cerebrovascular damage, such as thrombosis.

18. Participants taking drugs that affect the test for blood and lung.

19. Participants taking any traditional Chinese medicine.

20. Participants taking immune modulators such as Transfer Factor, Thymosin and Intravenous Immunoglobulin (IVIG), and so on.

21. Other cases that participants are considered by investigator that they did not meet the requirements for enrollment.

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Biological:
• UC-MSCs
The UC-MSCs will be administrated by intravenous injection at the dose of 1×10^6 cells/kg.

Locations

Country	Name	City	State
China	Xijing Hospital	Xi'an	Shaanxi

Sponsors (3)

Lead Sponsor	Collaborator
Xijing Hospital	Changhai Hospital, Southwest Hospital, China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Improvement rate of blood routine hemoglobin (HGB) compared to baseline.	The HGB increases by 10g compared to the baseline is considered improvement.	24 weeks
Primary	Improvement rate of forced vital capacity (FVC) and/or carbon monoxide diffusing capacity (DLCO) compared to baseline.	FVC increases by 0.5% and DLCO increases by 10% compared to baseline are considered improvement.	24 weeks
Secondary	The remission rates of American College of Rheumatology (ACR) 20, ACR 50 and ACR 70.	The patients achieves 20%, 50%, or 70% remission according to American College of Rheumatology (ACR) criteria.	12 weeks and 24 weeks
Secondary	White blood cell count and platelet count improved compared to the baseline.	White blood cell count increases to the 3.5×10^9/L and platelet count increases to 80×10^ 9.	12 weeks and 24 weeks
Secondary	Improvement rate of blood routine hemoglobin (HGB) compared to baseline.	The HGB increases by 10 g compared to the baseline is considered improvement.	12 weeks
Secondary	Improvement rate of forced vital capacity (FVC) and/or carbon monoxide	FVC increases by 0.5% and DLCO increases by 10% compared to baseline	12 weeks
Secondary	Image improvement of lung on high resolution CT.	The area change of image of lung.	24 weeks
Secondary	Improvement of 6-minute walking distance compared to baseline.		12 weeks and 24 weeks